This biotech stock is soaring 99% after Vertex agrees to takeover deal

Vertex Pharmaceuticals is buying an endocrine treatment specialist for $10 billion.

Crinetics shares surge after Vertex agrees to $10B cash buyout

With expected close this quarter, the stock should converge toward the deal price as deal certainty rises and spreads tighten ...
The Manila Times

Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis

Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-to-clinic journey in Nature Biotechnology, and ...
BioPharma Dive

Vertex to acquire Crinetics in $10B foray into endocrine disease drugs

Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it ...
Investor's Business Daily on MSN

Vertex Pharma makes a $10 billion deal; Crinetics stock doubles

Crinetics stock nearly doubled Tuesday after Vertex Pharmaceuticals pledged $10 billion to buy the endocrinology-focused biotech company.